文献速递帕金森病与运动障碍认知障碍与痴呆

多巴胺转运体显像缺损可预测特发性快速眼动睡眠行为障碍早期转化为突触核蛋白病

Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder.
PubMed 文献 · Ann Neurol · 2017-01-01

基线58.6%存在DAT缺损,随访中28.7%转化为临床定义的突触核蛋白病。DAT-SPECT异常者转化风险显著高于正常者(3年20% vs 6%,5年33% vs 18%,log rank P=0.006)。

要点

  • DAT-SPECT可用于识别IRBD患者短期转化为突触核蛋白病的风险。
  • 壳核FP-CIT摄取下降超过25%可区分3年内转化为突触核蛋白病的DAT缺损患者。
  • DAT-SPECT或有助于筛选IRBD患者进入疾病修饰试验。

核心结论

  • DAT-SPECT可识别IRBD患者短期发生突触核蛋白病的风险。
  • 壳核FP-CIT摄取下降大于25%可预测3年随访后发生突触核蛋白病。

研究设计与样本

  • 20例无RBD的匹配对照接受DAT-SPECT检查。
  • 患者FP-CIT摄取低于对照均值两个标准差时判为异常。
  • DAT-SPECT后随访5.7±2.2年(范围2.6-9.9年)。

主要发现

  • 基线DAT缺损见于51例(58.6%)患者。
  • 随访期间25例(28.7%)发生临床定义的突触核蛋白病(帕金森病11例、路易体痴呆13例、多系统萎缩1例),距显像平均潜伏期3.2±1.9年。
  • Kaplan-Meier分析显示DAT-SPECT异常者发生突触核蛋白病风险高于正常者(3年20% vs 6%,5年33% vs 18%;log rank检验P=0.006)。
  • ROC曲线显示壳核FP-CIT摄取下降大于25%可区分3年随访后发生与未发生突触核蛋白病的DAT缺损患者。
  • 5年随访时DAT-SPECT预测突触核蛋白病的敏感性75%、特异性51%、阳性预测值44%、阴性预测值80%、似然比1.54。

关键数值与推荐

  • DAT缺损判定:FP-CIT摄取低于对照均值两个标准差。
  • 壳核FP-CIT摄取下降大于25%为预测3年后突触核蛋白病的界值。
  • 5年随访预测效能:敏感性75%、特异性51%、阳性预测值44%、阴性预测值80%、似然比1.54。

临床怎么用

  • 对IRBD患者可考虑DAT-SPECT评估短期突触核蛋白病转化风险。
  • 壳核FP-CIT摄取下降大于25%提示3年内转化风险较高。
  • DAT-SPECT结果可用于筛选IRBD患者进入疾病修饰试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the usefulness of dopamine transporter (DAT) imaging to identify idiopathic rapid eye movement sleep behavior disorder (IRBD) patients at risk for short-term development of clinically defined synucleinopathy. METHODS: Eighty-seven patients with polysomnography-confirmed IRBD underwent 123 I-FP-CIT DAT-SPECT. Results were compared to 20 matched controls without RBD who underwent DAT-SPECT. In patients, FP-CIT uptake was considered abnormal when values were two standard deviations below controls' mean uptake. After DAT-SPECT, patients were followed up during 5.7 ± 2.2 (range, 2.6-9.9) years. RESULTS: Baseline DAT deficit was found in 51 (58.6%) patients. During follow-up, 25 (28.7%) subjects developed clinically defined synucleinopathy (Parkinson's disease in 11, dementia with Lewy bodies in 13, and multiple system atrophy in 1) with mean latency of 3.2 ± 1.9 years from imaging. Kaplan-Meier survival analysis showed increased risk of incident synucleinopathy in patients with abnormal DAT-SPECT than with normal DAT-SPECT (20% vs 6% at 3 years, 33% vs 18% at 5 years; log rank test, p = 0.006). Receiver operating characteristics curve revealed that reduction of FP-CIT uptake in putamen greater than 25% discriminated patients with DAT deficit who developed synucleinopathy from patients with DAT deficit that remained disease free after 3 years of follow-up. At 5-year follow-up, DAT-SPECT had 75% sensitivity, 51% specificity, 44% positive predictive value, 80% negative predictive value, and likelihood ratio 1.54 to predict synucleinopathy. INTERPRETATION: DAT-SPECT identifies IRBD patients at short-term risk for synucleinopathy. Decreased FP-CIT putamen uptake greater than 25% predicts synucleinopathy after 3 years' follow-up. These observations may be useful to select candidates for disease modification trials in IRBD. Ann Neurol 2017;82:419-428.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Iranzo A, Santamaría J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2017. PMID: 28833467. doi:10.1002/ana.25026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。